文献速递免疫规划

SARS-CoV-2刺突蛋白在嗜热毁丝霉C1中的表达与表征

Expression and characterization of SARS-CoV-2 spike protein in Thermothelomyces heterothallica C1.
PubMed 文献 · Vaccine · 2025-09-29

本研究在工程化丝状真菌嗜热毁丝霉C1中高效表达全长刺突糖蛋白,该蛋白热稳定性高,小鼠免疫后诱导体液免疫应答与哺乳动物平台表达产物相似。经广泛理化分析,C1产物性能与其他商业系统表达的刺突蛋白相似,且可修饰为更人源化唾液酸化聚糖谱而不影响结合特性。数据表明C1可作为生产复杂糖基化重组蛋白(如亚单位抗原疫苗)的强有力平台。

要点

  • 嗜热毁丝霉C1平台可高体积产率生产全长SARS-CoV-2刺突糖蛋白。
  • C1表达的刺突蛋白热稳定性高,小鼠免疫诱导体液免疫应答与哺乳动物平台表达产物相似。
  • C1产物可修饰为更人源化唾液酸化聚糖谱而不影响结合特性,理化性能与商业系统产物相似。

核心结论

  • C1平台可高体积产率生产全长刺突糖蛋白,该蛋白热稳定性高且小鼠免疫诱导体液免疫应答与哺乳动物平台产物相似,理化性能与其他商业系统产物相似。
  • 数据表明C1可作为生产复杂糖基化重组蛋白(如亚单位抗原疫苗)的强有力平台。

研究设计与样本

  • 本研究在工程化丝状真菌嗜热毁丝霉C1中表达全长SARS-CoV-2刺突糖蛋白,并对其进行理化表征及小鼠免疫原性评价。
  • 原文未报告样本量、分组数及统计检验方法。

主要发现

  • C1系统生产全长刺突糖蛋白具有高体积产率,该蛋白高度热稳定。
  • 小鼠免疫C1或哺乳动物平台表达的刺突蛋白,诱导体液免疫应答相似。
  • C1产物的天然N-聚糖谱可修饰为复杂唾液酸化结构,获得更人源化聚糖谱,实验与模拟显示不影响结合特性。
  • 广泛理化分析显示C1产物性能与其他商业可用系统表达的刺突蛋白相似。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 pandemic demonstrated a pressing need for rapid, adaptive, and scalable manufacturing of vaccines and reagents. With the transition into an endemic disease and rising threats of other emerging pandemics, production of these biologicals requires a stable and sustainable supply chain and accessible distribution methods. In this study, we demonstrate the strength of an engineered filamentous fungal platform, Thermothelomyces heterothallica C1, for high volumetric productivity of the full-length spike glycoprotein. Spike protein produced in this system is highly thermostable and immunization of mice with spike made in C1 or mammalian platforms resulted in a similar humoral response. Additionally, it was shown that the native N-glycan profile can be redecorated with complex sialylated structures, if necessary, resulting in a more human-like glycan profile, without impacting binding characteristics as shown experimentally and in simulations. Through extensive physicochemical analysis, the C1-produced spike performs similarly to spike proteins produced in other commercially available systems. The data presented is evidence that C1 can be a strong platform for production of complex glycosylated recombinant proteins such as subunit antigen vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ophir Y, Wong JH, Haddad KR, et al. Expression and characterization of SARS-CoV-2 spike protein in Thermothelomyces heterothallica C1. Vaccine. 2025. PMID: 41027158. doi:10.1016/j.vaccine.2025.127784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。